Mirogabalin...I think not!!

Hey fools, for anyone who is hanging on to this sinking ship (except for the few remaining legacy Daiich/Sankyo/DSI reps who are collecting a paycheck until the next layoff and hoping for packages similar to what was given in early 2016), there is no chance that Mirogabalin will be enough to save this train wreck.

Here's why:

*Only 2 indications: neuropathic pain, and DPN (neuropathic pain is a general diagnosis but could apply to DPN, FM, PHN and Spinal Cord Injury...the 3 indications that Pregabalin (Lyrica) already has FDA approval for).

*Pfizer banked $4.6 Billion in 2015 for Lyrica: yes, huge market, but DSI is no Pfizer.

* Really tough market to sell into

* Pregabalin and Gabapentic (Neurontin, also a Pfizer drug, generic since 1990's, indicated for neuropathic pain, seizures, PHN) dominate the market.

*Here's the death knell for DSI and Mirogabalin...Prgabalin goes generic in 2018, just about the time DSI hopes to launch Mirogabalin. With that being said, what are the chances DSI can penetrate the market unless they do what they did for Suckvaysa...give it away.

To make matters worse for DSI, their "TRIPLE WHAMMY GENERIC PAIN PILL" has ZERO chance for FDA approval. You think Charleston Pharma took that $40,000,000 and ran all the way to the bank.

Poor DSI.

Good luck boys and girls. I hope you guys make it.

 

Great post. Thanks for the honest information. Good luck to you as well.

 

I believe that we can win, I believe that we can win!

 

Where is the accountability for the failed US initiatives, for the poor US execution across the marketing and medical teams. How about business development folks in corporate & US who brought in these deals for us (MOV or CL), no accountability, just pats on the back and dinners at 5 star restaurants. Any other company, these folks would find empty moving boxes at their offices. I don't blame Japan HQ per se, as they are trying to leave it to the local people to figure out. Just a few weeks ago, the us medical lead for both Mirogab and CL- left for the west coast and greener pastures, didn't want to stay around for the inevitable FDA rejection of CL and the results of the mee-too Mirogab trials. Very sad, but gladly I am getting a check and waiting for the VSP package to get even sweeter. It's coming as MOV is again falling off the grid, but let's continue to smoke AZ with the minimum level of details so there doesn't have to be a payment to Wilmington...so goes the drama

 

Another great post. So true. It's going to get real nasty in immediate future.

 

hey Dr Glenn you better enjoy your boat off the coast of
Edison nj, its not long that your ship is going to be cast off
any not to basking ridge
you and ken have to be accountable for something other than offering a VSP every six months

 

Your really an idiot to out Glenn g and ken k in same sentence.
Gormley has and is responsible for development , he has delivered zippo .
Keller was dumb for buying Gormley bs and believing in suckvasa.
He was handed a bag of shit . I work in parsipanny , keller is straight shooter, he
Can't create drugs , that is Edison and Tokoyo.

We are all fucked , b/c of Gormley ...dumb ass

 

May be so but I have one question, if Ken is such a great leader that can't influence R&D, explain his choice for a Fuck up VP of sales Rob L?????

 

On behalf of the company, thanks for nothing Gormley! Your consistent failure will be your legacy

 

The opening post is full of factual errors. We paid the rednecks at Charleston $200 million upfront for rights to the triple generic. The industry people I spoke with thought we overpaid by a lot. The BD department goosed up the forecast to convince Tokyo to do this crap deal.

 

Well like the other post asked, explain Kens choice of Rob Ludicrous as VP of sales? You can tell slot from a person's so called trusted inner circle....

 

This is all true. The deal was inflated beyond reason just to convince Japan to make this deal. The original forecast was well over $1 billion, ridiculous. After we got control of this dog, the marketing team did a real forecast and it was barely $100 million at peak. And then that was inflated so Japan wouldn't freak out.

 

As for errors in there original post...find them.

My "fact checkers" from DSI payroll dept. verified each and every point!!

DSI paid $40mil for the rights to CL108, not $200mil. Not even DSI is that dumb and careless with cash.

Lyrica (Pregabalin) did produce near $5Billion (Billion with a B, not Million with an M) in sales in 2015 and does go generic in 2018, the same time Mirogabbadabbadoo will/might/maybe launch with ZERO chance of superiority and fewer indications. Miro can have 12 indications, superior efficacy and safety, and the $4 Savaysa Cash Card and not crack $200million with generic Pregabalin AND Gabapentin selling for $5 co-pays.

5 layoffs in 6 years, 1 re-org, and another on the way. DSI is no longer a respected pharma company and DSI reps are no longer valued in the industry.

Good luck!!

 

All true. Bernie Sanders fact checkers said so.

 

http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006170.html

See the start of the fifth paragraph in the pr above. Nice fact checking with payroll idiot.

 

Under the terms of the agreement, which is pending Hart-Scott-Rodinoclearance, Charleston Laboratories will receive $200 million, split evenly between an upfront cash payment and a near-term milestone and up to an additional $450 million in milestone payments connected to the filing and approval of its novel fixed-dose hydrocodone products in the United States. In addition, Charleston Laboratories will receive escalating, tiered, double-digit share of the gross operating margin from the products.

 

Wow! What a rip off. How stupid do you have to be? CL 108 will be a bigger dud than Sprix or Savaysa.

I'm ready for a change in senior leadership. Japan obviously has their heads up their butts and has no clue what K and R are doing to this company.

 

You may be right. Hydexor is going to bomb big time. There is no need for it in the market. Barrett took the fall for Savaysa. Switzer's clock is ticking on Movantik and Hydexor. Keller and Lisicki are not going anywhere for now.

 

follow the $$$ and watch whose getting rich.

 

The scientists getting paid to produce drugs to sell are responsible. Commercial is taking all the hits